Neurocrine Biosciences | NBIX - 销售和管理费用



金融业
股票价格
USD 167.40
资产
USD 5.63B
现金及等价物
USD 641.5M
销售成本
USD 61.6M
流动资产
USD 2.01B
流动负债
USD 984.6M
债务
USD 392.3M
EBIT
USD 343M
EBITDA
USD 375.3M
员工
1.8K
EPS每股收益
USD 3.29
股本和储备
USD 3.88B
销售毛利
USD 1.06B
债务利息支出
USD 300K
贷款资金
USD 169.5M
市值
USD 16.86B
净收入
USD 206.5M
营业费用
USD 779.7M
营业利润
USD 343M
普通股股本
USD 101.3M
PE价格收益
83.17
税前利润
USD 283.7M
销售收入
USD 1.12B
销售和管理费用
USD 366.3M
股票
USD 66.1M
贸易债权人
USD 754.1M
应收帐款人
USD 957.3M


销售和管理费用 更改 日
AbbVie USD 3.84B 205M 2026-09
Acadia Pharmaceuticals USD 146.88M 1.69M 2026-09
Agios Pharmaceuticals USD 51.55M 13.09M 2026-06
ALKERMES USD 190.54M 6.1M 2026-09
Alnylam Pharmaceuticals USD 342M 5.92M 2026-09
Amgen USD 1.68B 40M 2026-09
Biogen USD 752M 42.3M 2026-09
BioMarin Pharmaceutical USD 333.64M 61.91M 2026-09
Cytokinetics USD 113.14M 8.75M 2026-09
Enanta Pharmaceuticals USD -1.05 0.31 2024-12
Exelixis USD 154.56M 6.93M 2026-09
Gilead Sciences USD 1.52B 70M 2026-06
Halozyme Therapeutics USD 58.24M 1.24M 2026-09
Incyte USD 364.27M 12.54M 2026-09
Ionis Pharmaceuticals USD 154M 23.92M 2026-09
Nektar Therapeutics USD 11.87M 1.7M 2026-03
Neurocrine Biosciences USD 366.3M 16.8M 2026-09
Pfizer USD 3.28B 132M 2026-09
Prothena USD 10.9M 1.77M 2026-06
Regeneron Pharmaceuticals USD 662.1M 14.4M 2026-06
Repligen USD 83.59M 6.97M 2026-09
Rigel Pharmaceuticals USD 27.04M 1M 2024-09
Sarepta Therapeutics USD 118.61M 11.01M 2026-09
Teva Pharmaceutical Industries USD 1.01B 27M 2026-09
Ultragenyx Pharmaceutical USD 97M 9M 2026-09
Vertex Pharmaceuticals USD 556.3M 25.9M 2026-09